Cidara’s Anti-Fungal Receives Approval with Priority Review from US FDA
Rezzayo, Cidara Therapeutics’ newest anti-fungal drug, has received the nod from the US Food and Drug Administration (FDA) for approval under priority review for two kinds of candida infections, candidemia and invasive candidiasis. The drug is currently being reviewed by the EMA, which has already granted its marketing authorization approval.